Get the Stockscreener App
505.75
1.18%
5.89
After Hours:
505.75
Madrigal Pharmaceuticals Inc stock is traded at $505.75, with a volume of 486.96K.
It is up +1.18% in the last 24 hours and down -3.16% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$499.86
Open:
$500.38
24h Volume:
486.96K
Relative Volume:
1.56
Market Cap:
$11.66B
Revenue:
$1.13B
Net Income/Loss:
$-309.44M
P/E Ratio:
-39.51
EPS:
-12.8001
Net Cash Flow:
$-275.41M
1W Performance:
+6.64%
1M Performance:
-3.16%
6M Performance:
-7.10%
1Y Performance:
+78.89%
1-Day Range:
$485.56
$511.28
1-Week Range:
$469.07
$511.28
52-Week Range:
$276.67
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
505.75 | 11.66B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals Stockweekly review and NASH sector context - AD HOC NEWS
Madrigal Pharmaceuticals Inc - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants - Stock Titan
Madrigal Pharmaceuticals (MDGL) director granted RSUs and stock options - Stock Titan
Madrigal (MDGL) director James Daly granted RSUs and 766-share option - Stock Titan
Madrigal (MDGL) director receives stock grants and 681-share option award - Stock Titan
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards - Stock Titan
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes - Investing.com Nigeria
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Cooperating With NICE On MASH Drug After Provisional English Funding Rejection - Citeline News & Insights
Price-Driven Insight from (MDGL) for Rule-Based Strategy - Stock Traders Daily
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly - PharmaLive
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
MDGL Q1 2026 Earnings: Narrower Loss Surprises MarketsEarnings Yield Spread - lwvtexas.org
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. News — XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1 - TradingView
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
(MDGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Legal & General Group Plc Sells 6,440 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Insider Monkey
Madrigal Highlights Rezdiffra Data as MASH Market Expands - MyChesCo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - The Manila Times
12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Geode Capital Management LLC Has $263.11 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals targets liver disease with Rezdiffra, eyeing strong growth despite competition risks. - Pluang
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits - Quiver Quantitative
Insider Sell: David Soergel Sells Shares of Madrigal Pharmaceuti - GuruFocus
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):